Why dexamethasone could be a legitimate game-changer in the fight against COVID-19—and an update on the FDA and hydroxychloroquine.

A cardiologist at the University of Chicago Medicine has performed the first cardioneural ablation in U.S. history, using it to “rewire” the heart of a patient suffering from vasovagal syncope.

Treating atrial fibrillation (AF) patients with catheter ablation is associated with a decreased risk of mortality, heart failure admission and stroke, according to new findings published in the Journal of the American Heart Association.

Non-vitamin K antagonist oral anticoagulants are a valuable treatment option for atrial fibrillation patients with a prior intracranial hemorrhage, according to new findings published in JAMA Network Open. 

The association between COVID-19 and cardiac arrhythmias is significant, especially when patients are hit hard by the disease and moved to the ICU. 

Hydroxychloroquine and azithromycin are both associated with significant cardiovascular complications, and taking them together could be a deadly combination, according to new research published in Circulation.

New findings highlight why a blanket “do-not-resuscitate” order for COVID-19 patients is not needed. 

The news came just weeks after the FDA warned against treating COVID-19 with hydroxychloroquine “outside of the hospital setting or a clinical trial” due to significant cardiovascular complications.